No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Shanghai Henlius Kicks Off Pembrolizumab Biosimilar Trials in China
On 26 September 2025, Shanghai Henlius announced that the first patient has been dosed in its phase 1 multicentre clinical trial for HLX17, biosimilar to MSD’s Keytruda® (pembrolizumab).